Next Article in Journal
The Value of Infrared Thermography to Assess Foot and Limb Perfusion in Relation to Medical, Surgical, Exercise or Pharmacological Interventions in Peripheral Artery Disease: A Systematic Review
Next Article in Special Issue
Diffusion Tensor and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlate with Molecular Markers of Inflammation in the Synovium
Previous Article in Journal
MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies
Previous Article in Special Issue
Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 12
Issue 12
10.3390/diagnostics12123006
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Methylation of TET2 Promoter Is Associated with Global Hypomethylation and Hypohydroxymethylation in Peripheral Blood Mononuclear Cells of Systemic Lupus Erythematosus Patients

by
Wan-Yu Sung
1,*,
Yuan-Zhao Lin
1,
Daw-Yang Hwang
2,3,
Chia-Hui Lin
1,
Ruei-Nian Li
4,
Chia-Chun Tseng
1,5,
Cheng-Chin Wu
1,
Tsan-Teng Ou
1 and
Jeng-Hsien Yen
1,5,6,7,*
1
Division of Rheumatology, Department of Internal medicine, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan
2
National Institute of Cancer Research, National Health Research Institutes, Tainan 350401, Taiwan
3
Division of Nephrology, Department of Internal medicine, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan
4
Department of Biomedical Science and Environmental Biology, College of Life Science, Kaohsiung Medical University, Kaohsiung 80756, Taiwan
5
Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
6
College of Biological Science and Technology, National Chiao Tung University, Hsinchu 30010, Taiwan
7
Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan
*
Authors to whom correspondence should be addressed.
Diagnostics 2022, 12(12), 3006; https://doi.org/10.3390/diagnostics12123006
Submission received: 25 August 2022 / Revised: 28 November 2022 / Accepted: 28 November 2022 / Published: 1 December 2022
(This article belongs to the Special Issue Challenges in the Diagnosis and Management of Autoimmune Diseases)
Browse Figures
Review Reports Versions Notes

Abstract

:
(1) Background: It is widely accepted that aberrant methylation patterns contribute to the development of systemic lupus erythematosus (SLE). Ten–eleven translocation (TET) methylcytosine dioxygenase is an essential enzyme of which there are three members, TET1, 2, and 3, involved in hydroxymethylation, a newly uncovered mechanism of active DNA methylation. The epigenomes of gene transcription are regulated by 5-hydroxymethylcytocine (5-hmC) and TETs, leading to dysregulation of the immune system in SLE. The purpose of this study was to investigate the global hydroxymethylation status in SLE peripheral blood mononuclear cells (PBMCs) and to explore the role of TETs in changing the patterns of methylation. (2) Methods: We collected PBMCs from 101 SLE patients and 100 healthy donors. TaqMan real-time polymerase chain-reaction assay was performed for the detection of 5-methylcytosine (5-mC), 5-hmC, and TET2 mRNA expression and single-nucleotide polymorphism genotyping. The methylation rates in different CpG sites of TET2 promoters were examined using next-generation sequencing-based deep bisulfite sequencing. Putative transcription factors were investigated using the UCSC Genome Browser on the Human Dec. 2013 (GRCh38/hg38) Assembly. (3) Results: 5-mC and 5-hmC were both decreased in SLE. The mRNA expression level of TET2 was notably high and found to be correlated with the levels of immunologic biomarkers that are indicative of SLE disease activity. The analysis of methylation rates in the TET2 promoter revealed that SLE patients had significantly higher and lower rates of methylation in TET2 105146072-154 and TET2 105146218-331, respectively. (4) Conclusions: TET2 may play an important role in 5-mC/5-hmC dynamics in the PBMCs of SLE patients. The epigenetic modification of TET2 promoters could contribute to the pathogenesis of SLE and the intensity of the immunologic reaction.

1. Introduction

Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease characterized by hyperactivity of the immune system that results in multiple spontaneous inflammatory responses and subsequent tissue damage and organ failure. The dysregulation of immune responses is currently considered to be related to genes, sex hormones [1,2,3], and environmental factors (such as ultraviolet light, infections, free radicals, and environmental hormones) [4]. One study of homozygotic twins showed that the incidence of incomplete concordance is about 19–59% [5,6,7], which demonstrates that nongenetic factors play a pivotal role in the occurrence of SLE [6,8,9].
Epigenetic mechanisms include DNA methylation, miRNA interactions, and histone modification [10], of which the most important gene-regulation mechanism is DNA methylation. Among the research into nonhereditary causes of SLE, aberrant DNA methylation has attracted the most attention [11,12,13,14,15]. When the gene body loses its normal methylation pattern, the gene becomes abnormally activated, which can lead to dysgenesis, disease development, or survival failure of the organism. Although many studies have found many factors affecting DNA demethylation [12,13,14,15,16,17,18,19,20], it was not until 5-hydroxymethylcytosine (5-hmC) was identified in mammalian cells that there was a significant breakthrough in uncovering how the methyl group was removed from DNA in these cells.
The 5-hmC modification was first observed in the DNA of bacteriophages [21]. In mammals, 5-hmC is a product of 5-methylcytosine (5-mC) hydroxylation and referred to as hydroxymethylation, and it is further oxidized into other cytosine derivatives, 5-formylcytosine and 5-carboxycytosine [22,23,24,25], which are quite unstable and 100-fold less abundant than 5-hmC in the DNA-demethylation pathway [22,26,27].
The stepwise oxidation of 5-mC is catalyzed by ten–eleven translocation (TET) enzymes, which is one demethylation mechanism. TET protease is a family of three members, TET1, TET2, and TET3, which have similar crystallographic structures but whose genes are located on different chromosomes [28]. TETs, as methylcytosine dioxygenases, are indispensable for hydroxymethylation and may even serve as an influencing component of the rate-determination step [29]. Although TETs are observed to have different functions in different cells and tissues [29,30], knowledge of these functions is currently limited. For instance, TET1 and TET2 are highly expressed in mouse embryonic stem cells, whereas TET3 is largely expressed in the egg and single-cell zygote phase [31]. In TET knockout studies, it was found that TET1 is related to the body-size development of mice, TET2 is related to abnormal blood-cell function, and embryos lacking TET3 cannot survive or have extremely severe abnormalities [29]. Studies in humans have shown that mutations in TET2 are thought to be the most relevant of the various TETs in developing hematological malignancies [32,33,34] and are also associated with increased risks of autoimmunity in myelodysplastic syndrome patients [35].
The discovery of hydroxymethylation answered some questions on how methyl groups are lost from DNA and provided a clue for active DNA demethylation. The modification of 5-hmC is considered to be the sixth base in epigenetic modification that regulates DNA methylation patterns, whereas its precursor, 5-mC, is the fifth base [36]. It was found that the pathogenesis of SLE is closely related to aberrant methylation, so in our study, we aim to explore these two effects in SLE peripheral blood mononuclear cells (PBMCs) in addition to the interaction between hydroxymethylation and TET enzymes.

2. Materials and Methods

2.1. Patients

Samples of peripheral blood were obtained from SLE patients who had been diagnosed according to the 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for SLE [37]. These patients were all treated in the outpatient or inpatient department according to the clinical context. The healthy donors were recruited from the healthy population in the community. The process, involving informed consent, was approved by the Institutional Ethical Committee of Kaohsiung Medical University Hospital.

2.2. Methods

2.2.1. Isolation of Mononuclear Cells

PBMCs were isolated using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB, Concord, MA, USA).

2.2.2. Genomic DNA and RNA Extraction

The extraction of DNA and RNA was performed by using a Genomic DNA Extraction Kit (QIAGEN, Hilden, Germany) and RNA Blood Mini Kit (QIAamp, Ltd., Hilden, Germany), respectively, according to the manufacturer’s instructions.

2.2.3. DNA Methylation and Hydroxymethylation Assay

Global methylation and hydroxymethylation levels were quantified on total DNA using the MethylFlashTM Methylated DNA Quantification Kit (Epigentek, Farmingdale, NY, USA) and MethylFlashTM Hydroxymethylated DNA Quantification Kit (Epigentek, Farmingdale, NY, USA), respectively, according to the manufacturer’s instructions.

2.2.4. mRNA Expression of TETs

The mRNA expression levels of the target genes, TET1, TET2, and TET3, were quantified on RNA using Applied Biosystems TaqMan® Gene Expression Assays (TET1, Hs04189341; TET2, Hs00758658; TET3, Hs00379125). RNA polymerase II was used as an internal reference due to its constant and stable RNA-transcription level under stimulation [38].

2.2.5. Single-Nucleotide Polymorphism (SNP) Genotyping

TaqMan® SNP Genotyping Assays (Applied Biosystems. No. C_33251908, C_2551990, C_26458781) for TET2 gene polymorphism identification was used. Sequence detection of TaqMan real-time PCRs and genotyping analysis were performed using the ABI Prism 7500 system.

2.2.6. Next-Generation Sequencing (NGS)-Based Deep Bisulfite Sequencing

Deep bisulfite sequencing was performed according to the protocol proposed by Leitão et al. [39]. Bisulfite conversion of DNA was accomplished by using the EpiTect Fast DNA Bisulfite Kit (QIAGEN, Germany). After bisulfite treatment of DNA, PCR was used to amplify different sections of TET2 promoter using five pairs of forward and reverse primers (Table 1) designed using PyroMark Assay Design SW 2.0 (QIAGEN, Germany). First-round gene-specific PCRs were performed using the HotStarTaq Master Mix Kit (QIAGEN, Germany), which consisted of the initial hot start at 95 °C for 15 min followed by 50 cycles of denaturation at 94 °C for 30 s, annealing at 56 °C for 45 s, extension at 72 °C for 45 s, and a final extension phase at 72 °C for 10 min. The second PCR procedure was performed by using Index Adapters IDT® for Illumina Nextera DNA Unique Dual Indexes Set A (96 Indexes, 96 Samples) (Illumina, San Diego, CA, USA). PCR products were purified with Agencourt AMPure XP Beads (Beckman Coulter, Inc., Pasadena, CA, USA) and quantified using a QubitTM 1X dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). NGS was performed using the MiniSeq Mid Output Kit on the MiniSeq Illumina System (Illumina, USA) platform following the manufacturer’s instructions. The sequencing reaction was performed using 250 base paired-end sequencing. FASTQ files were further analyzed with the CLC Genomics Workbench v.10.0 Bisulfite Sequencing Plugin 2.1 (QIAGEN), which provides detailed nucleotide-level analysis, including the calculation of CpG methylation rates. Subsequent analysis of methylation rates was performed according to the criteria set by Masser et al. [40]. The putative transcription factors were searched from the UCSC Genome Browser on Human Dec. 2013 (GRCh38/hg38) Assembly.

2.3. Statistics

Statistical analysis was performed using the SPSS software, version 19, with t-testing for comparison of methylation and hydroxymethylation levels in the two populations in addition to methylation rates in various CpG sites of TET2. SNPs and the relationships between clinical manifestations and SNPs were analyzed using the chi-square test. Demographic data and TET1, TET2, and TET3 mRNA expression were analyzed using one-way analysis of variance (ANOVA). The correlations between the levels of TET mRNA vs. anti-dsDNA antibody and complement level vs. each CpG site were analyzed based on Spearman’s correlation. The confounder effect on global methylation, global hydroxymethylation, TET2 mRNA expression, and DNA methylation level was examined using multivariate linear-regression analysis. Causal-inference analysis was performed to explore the SLE disease status, global methylation/hydroxymethylation, and TET2 methylation. Statistical significance was defined as p < 0.05.

3. Results

We collected PBMCs from 101 SLE patients and 100 healthy donors. The demographic information is shown in Table 1.

3.1. Global Methylation and Hydroxymethylation

In the PBMCs of SLE and healthy donors, SLE patients had both global hypomethylation (5-mC in SLE and the healthy donors; 1.1093 ± 0.7103 vs. 1.3645 ± 0.8302, respectively; p = 0.021) and hypohydroxymethylation (5-hmC in SLE and the healthy donors; 0.0653 ± 0.0980 vs. 0.1091 ± 0.1326, respectively; p = 0.012), as shown in Table 2. To evaluate which variables affected the methylation pattern, multivariate regression was performed on age, gender, methotrexate, and cyclophosphamide as potential drivers of the difference in global methylation and hydroxymethylation, and the results are shown in Table 3.

3.2. TET mRNA Expression

In the healthy donors, the mRNA expression levels of TET genes all differed according to the following order, from highest to lowest: TET3 > TET2 > TET1 (Figure 1); in SLE, the TET2 and TET3 expression levels were significantly higher than those of TET1. Comparing the expression of every TET between SLE and the healthy donors, TET2 showed remarkably high levels in SLE (0.3293 ± 0.2139 vs. 0.2161 ± 0.1092, respectively; p < 0.001); the expressions of TET1 and TET3 did not differ between the two groups (Figure 1). The factors of age, gender, and medication were also statistically analyzed to assess the confounder effect on mRNA expression (Table 3).

3.3. TET2 mRNA and Immunologic Biomarkers

Immunologic tests of anti-dsDNA antibody and complement levels, as markers of SLE disease activity, are commonly available in the clinical context. An increase in anti-dsDNA antibody levels is a predictor of disease flare, and the complement level is correlated inversely with disease activity [41]. We found that TET2 mRNA expression was correlated with anti-dsDNA titers (r = 0.379, p < 0.01) and C3 and C4 levels (r = −0.257 and −0.328, p < 0.05 and <0.01, respectively; Table 4).

3.4. SNPs of TET2

We inspected whether SNPs counted for the increased expression of TET2 mRNA in SLE patients. Five SNPs (rs17035311, rs11729069, rs7661349, rs1007915, and rs62331150) with a minor allelic frequency (MAF) > 0.2 in Hans were chosen for testing. Three SNPs, rs17035311, rs7661349, and rs62331150, were analyzed because they were not involved in a linked pair (rs17035311 vs. rs11729069 and rs7661349 vs. rs1007915) (Figure 2). However, no statistically significant correlations were observed for any of the tested SNPs (Supplementary Table S1).

3.5. Methylation Rates of TET2

We examined 40 CpG sites in the TET2 promoter. Compared with healthy donors, the SLE patients had significantly different methylation rates at two sites, TET2 105146116 and 105146718 (p = 0.048 and 0.040, respectively, as shown in Table 5). In SLE patients, the methylation rates were higher at TET2 105146116 but lower at TET2 105146718 than in the healthy donors. In region 105146072-154 and 105146218-331, there were even more significant differences in methylation rates (the examined CpG sites in the regions that had significant differences in methylation rates between SLE and healthy donors are shown in Supplementary Table S2) We then performed multivariate linear regression to analyze whether the methylation level in the CpG sites and regions with significance were influenced by age, gender, and medication (Table 6). However, the analysis demonstrated that the methylation level of CpGs was not driven by these variables.

3.6. The Relationships of SLE Disease Status and Global Methylation, Hydroxymethylation, and TET2 Methylation

We tried to directly link the relationships of TET2 methylation and global methylation or global hydroxymethylation in SLE, but no significant correlation was shown. In addition, we tested whether the SLE disease status or global methylation level was affected by TET2 methylation by causal inference analysis, but no significance was denoted (Supplementary Tables S3 and S4).

4. Discussion

In this study, we showed that altered methylation of TET2 is involved in the dynamics of 5-mC and 5-hmC, contributing to the alteration of global DNA-methylation patterns in SLE PBMCs. Moreover, TET2 mRNA levels are positively associated with anti-dsDNA and negatively associated with complement levels, a proxy for the disease activity of SLE. The differences in global methylation, hydroxymethylation, TET2 mRNA expression, and methylation rates in TET2 CpG sites or regions between SLE the healthy donors were found to be independent of age, gender, and medication (methotrexate and cyclophosphamide).
Prior studies have indicated that the significant hypomethylation of interferon-regulated genes in T cells plays a pivotal role in SLE pathogenesis. Hypomethylated interferon-regulated genes are present in patients during flares and remission, suggesting that it is an early and persistent phenomenon in SLE [42,43]. In the findings of Mok et al., hypomethylation of HIF-related genes IFI44 and PRR4 was found to be associated with lupus nephritis [44], and the hypomethylated IL10 and IL1R2 genes were associated with disease activity [11]. In summary, genome-wide DNA-methylation studies have found that a decrease in the DNA-methylation level of genes is associated with SLE susceptibility [9], which is compatible with the global hypomethylation observed in the PBMCs of SLE patients in this study and our previous study [45].
There is emerging evidence showing that 5-hmC is an independent and epigenetic marker distinct from 5-mC and able to exert regulatory functions itself to influence gene transcription. In our study, we observed global hypohydroxymethylation in the PBMCs of SLE patients compared with healthy donors. Given the premise that DNA demethylation occurs through 5-mC dynamics, it has been observed that the depletion of hydroxymethylation-conferring TET proteins does not necessarily result in increased DNA methylation [29,46]. The correlation analysis of TET2 methylation and global methylation or hydroxymethylation failed to show a positive correlation, which implies that the 5-mc/5-hmc dynamics was not as straightforward as depicted in the chemical equation and that the role of TET2 methylation in the pathogenesis of SLE disease development must be far more complicated and yet to be fully elucidated. Zhao et al. identified 47 genes with decreased 5-hmC levels in their promoter regions in SLE CD4+ T cells and 2748 genes with increased 5-hmC levels in comparison with healthy donors [14]. Sui et al. reported that cyclin-dependent kinase inhibitor 1B (CDKN1B) exhibited significantly decreased levels of 5-hmC in the PBMCs of SLE patients, whereas three prime repair exonuclease (TREX1) and CDKN1A showed increased levels of 5-hmC [47]. The differential patterns of hydroxymethylation involving immune-related cells or key cytokine genes in the pathway leading to inflammation contributes to SLE pathogenesis. However, whether this is due to over- or underexpression of 5-hmC depends on the context, and how 5-hmC exerts itself to switch genes on or off has yet to be described.
Studies in human TET proteases have shown that mutations in TET2 are most relevant to developing hematological malignancies [32,33,34] and are also associated with increased risks of autoimmunity in myelodysplastic syndrome patients [35]. TET2 and TET3 are expressed at higher levels than TET1 in peripheral T cells, and TET3 is believed to compensate for the loss of function of TET2 [48]. Our findings are consistent with this, wherein TET2 and TET3 were observed to be dominantly expressed in both SLE and healthy donors. Recently, it was found that TET2 masters important regulatory functions in the differentiation of T cells [49,50,51]. By affecting active DNA demethylation, it is possible to precisely regulate the maturation and expression of the signature cytokines of Th1 and Th17 [49]. SLE has previously been considered a “B-cell disease” due to the variety of autoantibodies produced by B cells as the culprits in SLE pathophysiology. However, studies are increasingly showing that T-cell dysfunction plays a more decisive role in the pathogenesis of SLE, including abnormal hyperactivity of Th17, changes in T-cell receptors, abnormalities in the related signaling pathways, and the dysfunction of T cells that regulate the ability to suppress inflammation [52]. This study used PBMCs, which are a heterogeneous mixture of mononuclear cells, as the experimental material, and T cells were the main components. TET2 gene expression was significantly increased in SLE in this study, indicating that TET2 may be involved in the pathogenesis of SLE by affecting DNA demethylation in T cells.
Clinically, serum levels of anti-dsDNA and complement concentrations (C3 and C4) are used as proxies to monitor disease activation and serve as one of the parameters of treatment response, which is supported by previous studies [41]. In this study, we found that the levels of TET2 mRNA were also significantly correlated with those of anti-dsDNA, C3, and C4. TET2 may have regulatory capabilities that affect overall immune function. However, more in-depth research is required to clarify whether the increase in TET2 expression initiates or occurs in response to disease activity.
Although we observed that TET2 mRNA expression varies in SLE patients, we assume that this was due to phenotypic variance. Three TET2 SNPs were analyzed, and no statistically significant associations with disease were found. Meta-analysis of genome-wide associations for SLE have previously resulted in the identification of genetic variants in TET3 (rs6705628, rs4852324, and rs10207954) as susceptibility loci in Asian populations [53,54].
In our study, we demonstrated that, in SLE, the methylation rates were significantly lower in TET2 Chr 4: 105146218-718 and significantly higher in Chr 4: 105146072-154. In Chr 4: 105146218-718, several transcriptional activators involving the noncanonical NF-kappa-B pathway were noted, such as DPF2 and RELB [55]. Dysregulation of noncanonical NF-κB activation affects various immune cells to different extents, such as (i) causing aberrant survival of self-reactive B cells, rendering them resistant to negative selection and leading to autoimmune antibody production associated with a number of autoimmune diseases, and (ii) resulting in aberrant chemokine production and inflammatory-cell recruitment in endothelial cells, T cells, and monocytes by diverse mechanisms [55]. In Chr 4: 105146116-154, where there is hypermethylation of CpG sites, there is also a binding site for the repressive transcription factor, enhancer of zeste homolog 2 (EZH2), which might play a key role in the T-cell epigenetic conformational changes that are associated with disease flare in lupus [51]. EZH2 reduces H3K27 trimethylation by the PI3K/AKT pathway, resulting in decreased binding between EZH2 and H3K27 [56,57]. In somatic-cell types and cancer-cell lines, H3K27me3 overlaps extensively with DNA methylation [58]. Hypermethylated regions correlated with higher disease activity of SLE were found to be enriched in binding sites for the repressive transcription factor EZH2 [51]. Consequently, downstream TET2 genes might become transcriptionally activated from a state of inhibition, resulting in increased levels of TET2 mRNA expression.
There are limitations to the study. First, our study used an ELISA technique to analyze the difference in methylation and hydroxymethylation. The technique does not allow differences to be shown in individual genes that may not be reflected in global changes. Second, although T lymphocytes are the majority, PBMC contains a variety of mononuclear cells, which could affect DNA methylation as an intrinsic factor, whereas DNA-methylation patterns are known to be tissue/cell specific and affect disease-phenotype differences. Finally, in a cross-sectional study like ours, only association and not the causal relationship between global methylation, global hydroxymethylation, and methylation level of TET2 is denoted.

5. Conclusions

In conclusion, this study delineated global hypomethylation and hypohydroxymethylation in the PBMCs of SLE patients and demonstrated, for the first time, that methylation of the TET2 gene during SLE development and its mRNA expression are correlated with disease activity.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics12123006/s1, Table S1. Polymorphism of TETs in systemic lupus erythematosus and the controls; Table S2. CpG sites contained in the regions which have significant difference in methylation levels between SLE and health donors; Table S3. The correlation of TET2 methylation level and global methylation or global hydroxymethylation; Table S4. The interaction of TET2 methylation and SLE disease status. Figure S1. Correlation(r) between TETs mRNA and disease activity of systemic lupus erythematosus, defined by levels of anti-dsDNA, C3 and C4.

Author Contributions

Conceptualization, W.-Y.S. and J.-H.Y.; methodology, Y.-Z.L. and R.-N.L.; validation, R.-N.L., C.-C.T., C.-C.W. and T.-T.O.; investigation, W.-Y.S., Y.-Z.L. and C.-H.L.; resources, D.-Y.H. and J.-H.Y.; data curation, Y.-Z.L. and C.-H.L.; writing—original draft, W.-Y.S.; supervision, J.-H.Y.; project administration, W.-Y.S., Y.-Z.L. and C.-H.L.; funding acquisition, W.-Y.S. and J.-H.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Kaohsiung Medical University Hospital, grant number KMUH103-3M13, and by the National Science and Technology Council, grant number MOST111-2314-B-037-084.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of Kaohsiung Medical University (KMUHIRB-20140092, 11 August 2014).

Informed Consent Statement

Informed consent was obtained from all the subjects involved in the study.

Data Availability Statement

Not applicable.

Acknowledgments

The authors appreciate the Center for Bioinformatics and Digital Health at National Cheng Kung University, supported by the National Science and Technology Council, Taiwan, for computational analyses and data mining for NGS, and the Division of Medical Statistics and Bioinformatics, Department of Medical Research, Kaohsiung Medical University Hospital, and Center for Big Data Research (KMU-TC109B08), Kaohsiung Medical University, for providing statistical support, including the Kaohsiung Medical University Hospital Research Database (KMUHRD).

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Young, N.A.; Valiente, G.R.; Hampton, J.M.; Wu, L.-C.; Burd, C.J.; Willis, W.L.; Bruss, M.; Steigelman, H.; Gotsatsenko, M.; Amici, S.A.; et al. Estrogen-regulated STAT1 activation promotes TLR8 expression to facilitate signaling via microRNA-21 in systemic lupus erythematosus. Clin. Immunol. 2017, 176, 12–22. [Google Scholar] [CrossRef] [PubMed]
  2. Cunningham, M.A.; Naga, O.S.; Eudaly, J.G.; Scott, J.L.; Gilkeson, G.S. Estrogen receptor alpha modulates toll-like receptor signaling in murine lupus. Clin. Immunol. 2012, 144, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Feng, F.; Nyland, J.; Banyai, M.; Tatum, A.; Silverstone, A.E.; Gavalchin, J. The induction of the lupus phenotype by estrogen is via an estrogen receptor-α-dependent pathway. Clin. Immunol. 2010, 134, 226–236. [Google Scholar] [CrossRef]
  4. Podolska, M.J.; Biermann, M.H.; Maueroder, C.; Hahn, J.; Herrmann, M. Inflammatory etiopathogenesis of systemic lupus erythematosus: An update. J. Inflamm. Res. 2015, 8, 161–171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Block, S.R.; Winfield, J.B.; Lockshin, M.D.; D’Angelo, W.A.; Christian, C.L. Studies of twins with systemic lupus erythematosus. Am. J. Med. 1975, 59, 533–552. [Google Scholar] [CrossRef] [PubMed]
  6. Deapen, D.; Escalante, A.; Weinrib, L.; Horwitz, D.; Bachman, B.; Roy-Burman, P.; Walker, A.; Mack, T.M. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheumatol. 1992, 35, 311–318. [Google Scholar]
  7. Kyttaris, V.C. Systemic lupus erythematosus: From genes to organ damage. Methods Mol. Biol. 2010, 662, 265–283. [Google Scholar] [CrossRef] [Green Version]
  8. Edwards, C.J.; James, J.A. Making lupus: A complex blend of genes and environmental factors is required to cross the disease threshold. Lupus 2006, 15, 713–714. [Google Scholar] [CrossRef] [Green Version]
  9. Javierre, B.M.; Fernandez, A.F.; Richter, J.; Al-Shahrour, F.; Martin-Subero, J.I.; Rodriguez-Ubreva, J.; Berdasco, M.; Fraga, M.F.; O’Hanlon, T.P.; Rider, L.G.; et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010, 20, 170–179. [Google Scholar] [CrossRef] [Green Version]
  10. Handy, D.E.; Castro, R.; Loscalzo, J. Epigenetic Modifications: Basic Mechanisms and Role in Cardiovascular Disease. Circulation 2011, 123, 2145–2156. [Google Scholar] [CrossRef] [Green Version]
  11. Lin, S.Y.; Hsieh, S.C.; Lin, Y.C.; Lee, C.N.; Tsai, M.H.; Lai, L.C.; Chuang, E.Y.; Chen, P.C.; Hung, C.C.; Chen, L.Y.; et al. A whole genome methylation analysis of systemic lupus erythematosus: Hypomethylation of the IL10 and IL1R2 promoters is associated with disease activity. Genes Immun. 2012, 13, 214–220. [Google Scholar] [CrossRef] [PubMed]
  12. Wu, H.; Zhao, M.; Chang, C.; Lu, Q. The real culprit in systemic lupus erythematosus: Abnormal epigenetic regulation. Int. J. Mol. Sci. 2015, 16, 11013–11033. [Google Scholar] [CrossRef] [PubMed]
  13. Zhao, M.; Wang, Z.; Yung, S.; Lu, Q. Epigenetic dynamics in immunity and autoimmunity. Int. J. Biochem. Cell Biol. 2015, 67, 65–74. [Google Scholar] [CrossRef] [PubMed]
  14. Zhao, M.; Wang, J.; Liao, W.; Li, D.; Li, M.; Wu, H.; Zhang, Y.; Gershwin, M.E.; Lu, Q. Increased 5-hydroxymethylcytosine in CD4+ T cells in systemic lupus erythematosus. J. Autoimmun. 2016, 69, 64–73. [Google Scholar] [CrossRef]
  15. Chen, S.H.; Lv, Q.L.; Hu, L.; Peng, M.J.; Wang, G.H.; Sun, B. DNA methylation alterations in the pathogenesis of lupus. Clin. Exp. Immunol. 2017, 187, 185–192. [Google Scholar] [CrossRef] [Green Version]
  16. Wu, H.Y.; Behe, M.J. Salt induced transitions between multiple conformations of poly (rG-m5dC), poly (rG-m5dC). Nucleic Acids Res. 1985, 13, 3931–3940. [Google Scholar] [CrossRef] [Green Version]
  17. Ho, L.; Bohr, V.A.; Hanawalt, P.C. Demethylation enhances removal of pyrimidine dimers from the overall genome and from specific DNA sequences in Chinese hamster ovary cells. Mol. Cell. Biol. 1989, 9, 1594–1603. [Google Scholar]
  18. Quddus, J.; Johnson, K.J.; Gavalchin, J.; Amento, E.P.; Chrisp, C.E.; Yung, R.L.; Richardson, B.C. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J. Clin. Investig. 1993, 92, 38–53. [Google Scholar] [CrossRef] [Green Version]
  19. Chen, H.; Liu, J.; Zhao, C.Q.; Diwan, B.A.; Merrick, B.A.; Waalkes, M.P. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation. Toxicol. Appl. Pharmacol. 2001, 175, 260–268. [Google Scholar] [CrossRef]
  20. Pol Bodetto, S.; Carouge, D.; Fonteneau, M.; Dietrich, J.B.; Zwiller, J.; Anglard, P. Cocaine represses protein phosphatase-1Cbeta through DNA methylation and Methyl-CpG Binding Protein-2 recruitment in adult rat brain. Neuropharmacology 2013, 73, 31–40. [Google Scholar] [CrossRef]
  21. Wyatt, G.R.; Cohen, S.S. A New Pyrimidine Base from Bacteriophage Nucleic Acids. Nature 1952, 170, 1072–1073. [Google Scholar] [CrossRef]
  22. Liang, J.; Yang, F.; Zhao, L.; Bi, C.; Cai, B. Physiological and pathological implications of 5-hydroxymethylcytosine in diseases. Oncotarget 2016, 7, 48813–48831. [Google Scholar] [CrossRef] [PubMed]
  23. Bhutani, N.; Burns, D.M.; Blau, H.M. DNA demethylation dynamics. Cell 2011, 146, 866–872. [Google Scholar] [CrossRef] [Green Version]
  24. Schomacher, L. Mammalian DNA demethylation. Epigenetics 2013, 8, 679–684. [Google Scholar] [CrossRef] [Green Version]
  25. Shukla, A.; Sehgal, M.; Singh, T.R. Hydroxymethylation and its potential implication in DNA repair system: A review and future perspectives. Gene 2015, 564, 109–118. [Google Scholar] [CrossRef] [PubMed]
  26. Tahiliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L.; et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324, 930–935. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Ito, S.; Shen, L.; Dai, Q.; Wu, S.C.; Collins, L.B.; Swenberg, J.A.; He, C.; Zhang, Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333, 1300–1303. [Google Scholar] [CrossRef] [Green Version]
  28. Akahori, H.; Guindon, S.; Yoshizaki, S.; Muto, Y. Molecular Evolution of the TET Gene Family in Mammals. Int. J. Mol. Sci. 2015, 16, 28472–28485. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Tan, L.; Shi, Y.G. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 2012, 139, 1895–1902. [Google Scholar] [CrossRef] [Green Version]
  30. Nguyen, S.; Meletis, K.; Fu, D.; Jhaveri, S.; Jaenisch, R. Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan. Dev. Dyn. 2007, 236, 1663–1676. [Google Scholar] [CrossRef]
  31. Ficz, G.; Branco, M.R.; Seisenberger, S.; Santos, F.; Krueger, F.; Hore, T.A.; Marques, C.J.; Andrews, S.; Reik, W. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011, 473, 398–402. [Google Scholar] [CrossRef] [PubMed]
  32. Chiba, S. Dysregulation of TET2 in hematologic malignancies. Int. J. Hematol. 2017, 105, 17–22. [Google Scholar] [CrossRef] [PubMed]
  33. Figueroa, M.E.; Abdel-Wahab, O.; Lu, C.; Ward, P.S.; Patel, J.; Shih, A.; Li, Y.; Bhagwat, N.; Vasanthakumar, A.; Fernandez, H.F.; et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18, 553–567. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Ko, M.; Huang, Y.; Jankowska, A.M.; Pape, U.J.; Tahiliani, M.; Bandukwala, H.S.; An, J.; Lamperti, E.D.; Koh, K.P.; Ganetzky, R.; et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468, 839–843. [Google Scholar] [CrossRef] [Green Version]
  35. Oh, Y.J.; Shin, D.Y.; Hwang, S.M.; Kim, S.M.; Im, K.; Park, H.S.; Kim, J.A.; Song, Y.W.; Márquez, A.; Martín, J.; et al. Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome. Korean J. Intern. Med. 2020, 35, 457–464. [Google Scholar] [CrossRef] [Green Version]
  36. Song, C.X.; He, C. The hunt for 5-hydroxymethylcytosine: The sixth base. Epigenomics 2011, 3, 521–523. [Google Scholar] [CrossRef] [Green Version]
  37. Aringer, M.; Costenbader, K.; Daikh, D.; Brinks, R.; Mosca, M.; Ramsey-Goldman, R.; Smolen, J.S.; Wofsy, D.; Boumpas, D.T.; Kamen, D.L.; et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019, 71, 1400–1412. [Google Scholar] [CrossRef] [Green Version]
  38. Radonić, A.; Thulke, S.; Mackay, I.M.; Landt, O.; Siegert, W.; Nitsche, A. Guideline to reference gene selection for quantitative real-time PCR. Biochem. Biophys. Res. Commun. 2004, 313, 856–862. [Google Scholar] [CrossRef]
  39. Leitao, E.; Beygo, J.; Zeschnigk, M.; Klein-Hitpass, L.; Bargull, M.; Rahmann, S.; Horsthemke, B. Locus-Specific DNA Methylation Analysis by Targeted Deep Bisulfite Sequencing. Methods Mol. Biol. 2018, 1767, 351–366. [Google Scholar] [CrossRef]
  40. Masser, D.R.; Stanford, D.R.; Freeman, W.M. Targeted DNA methylation analysis by next-generation sequencing. J. Vis. Exp. 2015, 96, e52488. [Google Scholar] [CrossRef] [Green Version]
  41. Illei, G.G.; Tackey, E.; Lapteva, L.; Lipsky, P.E. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004, 50, 2048–2065. [Google Scholar] [CrossRef] [PubMed]
  42. Coit, P.; Jeffries, M.; Altorok, N.; Dozmorov, M.G.; Koelsch, K.A.; Wren, J.D.; Merrill, J.T.; McCune, W.J.; Sawalha, A.H. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J. Autoimmun. 2013, 43, 78–84. [Google Scholar] [CrossRef] [PubMed]
  43. Teruel, M.; Sawalha, A.H. Epigenetic Variability in Systemic Lupus Erythematosus: What We Learned from Genome-Wide DNA Methylation Studies. Curr. Rheumatol. Rep. 2017, 19, 32. [Google Scholar] [CrossRef] [PubMed]
  44. Mok, A.; Solomon, O.; Nayak, R.R.; Coit, P.; Quach, H.L.; Nititham, J.; Sawalha, A.H.; Barcellos, L.F.; Criswell, L.A.; Chung, S.A. Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type 1 interferon responses. Lupus Sci. Med. 2016, 3, e000183. [Google Scholar] [CrossRef] [Green Version]
  45. Liu, C.C.; Ou, T.T.; Wu, C.C.; Li, R.N.; Lin, Y.C.; Lin, C.H.; Tsai, W.C.; Liu, H.W.; Yen, J.H. Global DNA methylation, DNMT1, and MBD2 in patients with systemic lupus erythematosus. Lupus 2011, 20, 131–136. [Google Scholar] [CrossRef] [PubMed]
  46. Li, Y.; Seah, M.K.; O’Neill, C. Mapping global changes in nuclear cytosine base modifications in the early mouse embryo. Reproduction 2016, 151, 83–95. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Sui, W.; Tan, Q.; Yang, M.; Yan, Q.; Lin, H.; Ou, M.; Xue, W.; Chen, J.; Zou, T.; Jing, H.; et al. Genome-wide analysis of 5-hmC in the peripheral blood of systemic lupus erythematosus patients using an hMeDIP-chip. Int. J. Mol. Med. 2015, 35, 1467–1479. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Lio, C.-W.J.; Rao, A. TET Enzymes and 5hmC in Adaptive and Innate Immune Systems. Front. Immunol. 2019, 10, 210. [Google Scholar] [CrossRef] [Green Version]
  49. Ichiyama, K.; Chen, T.; Wang, X.; Yan, X.; Kim, B.S.; Tanaka, S.; Ndiaye-Lobry, D.; Deng, Y.; Zou, Y.; Zheng, P.; et al. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 2015, 42, 613–626. [Google Scholar] [CrossRef] [Green Version]
  50. Yang, R.; Qu, C.; Zhou, Y.; Konkel, J.E.; Shi, S.; Liu, Y.; Chen, C.; Liu, S.; Liu, D.; Chen, Y.; et al. Hydrogen Sulfide Promotes Tet1- and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis. Immunity 2015, 43, 251–263. [Google Scholar] [CrossRef] [Green Version]
  51. Coit, P.; Dozmorov, M.G.; Merrill, J.T.; McCune, W.J.; Maksimowicz-McKinnon, K.; Wren, J.D.; Sawalha, A.H. Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non-Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares. Arthritis Rheumatol. 2016, 68, 2200–2209. [Google Scholar] [CrossRef] [Green Version]
  52. Mak, A.; Kow, N.Y. The Pathology of T Cells in Systemic Lupus Erythematosus. J. Immunol. Res. 2014, 2014, 8. [Google Scholar] [CrossRef] [PubMed]
  53. Yang, W.; Tang, H.; Zhang, Y.; Tang, X.; Zhang, J.; Sun, L.; Yang, J.; Cui, Y.; Zhang, L.; Hirankarn, N.; et al. Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am. J. Hum. Genet. 2013, 92, 41–51. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Yin, X.; Kim, K.; Suetsugu, H.; Bang, S.Y.; Wen, L.; Koido, M.; Ha, E.; Liu, L.; Sakamoto, Y.; Jo, S.; et al. Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. Ann. Rheum. Dis. 2021, 80, 632–640. [Google Scholar] [CrossRef] [PubMed]
  55. Sun, S.C. The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol. 2017, 17, 545–558. [Google Scholar] [CrossRef] [PubMed]
  56. Cha, T.-L.; Zhou, B.P.; Xia, W.; Wu, Y.; Yang, C.-C.; Chen, C.-T.; Ping, B.; Otte, A.P.; Hung, M.-C. Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3. Science 2005, 310, 306–310. [Google Scholar] [CrossRef] [PubMed]
  57. Spangle, J.M.; Dreijerink, K.M.; Groner, A.C.; Cheng, H.; Ohlson, C.E.; Reyes, J.; Lin, C.Y.; Bradner, J.; Zhao, J.J.; Roberts, T.M.; et al. PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Rep. 2016, 15, 2692–2704. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Rose, N.R.; Klose, R.J. Understanding the relationship between DNA methylation and histone lysine methylation. Biochim. Biophys. Acta BBA Gene Regul. Mech. 2014, 1839, 1362–1372. [Google Scholar] [CrossRef] [PubMed]
Diagnostics 12 03006 g001 550
Figure 1. mRNA expression of TETs in systemic lupus erythematosus and healthy donors. TET2 was remarkably high in SLE, ** p < 0.001. p-values were obtained using ANOVA tests.
Figure 1. mRNA expression of TETs in systemic lupus erythematosus and healthy donors. TET2 was remarkably high in SLE, ** p < 0.001. p-values were obtained using ANOVA tests.
Diagnostics 12 03006 g001
Diagnostics 12 03006 g002 550
Figure 2. Linkage-disequilibrium plot for TET2 SNPs. To avoid genetic linkage, which can lead to issues in multiple comparisons, a heatmap was created using an interactive online tool (https://Idlink.nci.nih.gove/?tab=Idmatrix, accessed on 20 September 2020) to understand the patterns of linkage disequilibrium between SNPs.
Figure 2. Linkage-disequilibrium plot for TET2 SNPs. To avoid genetic linkage, which can lead to issues in multiple comparisons, a heatmap was created using an interactive online tool (https://Idlink.nci.nih.gove/?tab=Idmatrix, accessed on 20 September 2020) to understand the patterns of linkage disequilibrium between SNPs.
Diagnostics 12 03006 g002
Table
Table 1. Demographic data of systemic lupus erythematosus and healthy donors.
Table 1. Demographic data of systemic lupus erythematosus and healthy donors.
FemaleMale
SLE
(n = 91)		Health Donors
(n = 76)		pSLE
(n = 10)		Health Donors
(n = 21)		p
Age (mean ± SD)38.34 ± 11.1435.64 ± 10.240.10834.3 ± 15.933.4 ± 15.170.878
   <202020
   20–30222433
   30–402425212
   40–50272413
   >5016322
Drugs
   Methotrexate4N/A2N/A
   Cyclophosphamide23N/A3N/A
SD, standard deviation. SLE, systemic lupus erythematosus. N/A, not applicable. p-values were obtained using t-tests.
Table
Table 2. Global methylation and hydroxymethylation in the PBMCs of systemic lupus erythematosus patients and healthy donors.
Table 2. Global methylation and hydroxymethylation in the PBMCs of systemic lupus erythematosus patients and healthy donors.
SLE
(n = 101)		Healthy Donors
(n = 100)		pa
5-mC (%, mean ± SD)1.109 ± 0.7101.365 ± 0.8300.021
5-hmC (%, mean ± SD)0.063 ± 0.0970.109 ± 0.1330.012
SLE, systemic lupus erythematosus; 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine; SD, standard deviation. p-values were obtained using t-tests. a p < 0.05.
Table
Table 3. Multivariate linear regression of factors related to alteration of methylation pattern.
Table 3. Multivariate linear regression of factors related to alteration of methylation pattern.
5-mC5-hmCTET2 mRNA
βpβpβp
Age−0.1500.142−0.1310.3790.0340.737
Gender0.1230.9030.0520.111−0.0270.795
Methotrexate−0.1760.086−0.0180.8620.1510.155
Cyclophosphamide−0.1120.2700.1440.1630.1180.253
β: β-coefficient; p: p-value.
Table
Table 4. Correlation (r) between TET mRNA and disease activity of systemic lupus erythematosus, defined by levels of anti-dsDNA, C3, and C4.
Table 4. Correlation (r) between TET mRNA and disease activity of systemic lupus erythematosus, defined by levels of anti-dsDNA, C3, and C4.
mRNAAnti-dsDNAC3C4
TET1−0.0960.119−0.017
TET20.379 **−0.257 *−0.328 **
TET30.018−0.179−0.185
* p < 0.05; ** p < 0.01; correlation (r) values were obtained using Spearman’s correlation tests. Scatter plots shown in Supplementary Materials.
Table
Table 5. Methylation rates at various CpG sites of TET2 promoters.
Table 5. Methylation rates at various CpG sites of TET2 promoters.
CpGSLE (%)Healthy Donor (%)pa
1051461161.222 ± 1.2370.712 ± 0.6460.048
105146072-1544.738 ± 2.5333.310 ± 1.2070.006
105146218-3311.242 ± 0.5621.644 ± 0.6490.014
1051467180.526 ± 0.2880.736 ± 0.4630.040
SLE: systemic lupus erythematosus. a p-value was obtained by t-test.
Table
Table 6. Multivariate regression of factors relevant to TET2-promoter methylation rates.
Table 6. Multivariate regression of factors relevant to TET2-promoter methylation rates.
105146116105146072-154105146218-331105146718
βpβpβpβp
Age−0.2940.051−0.8880.379−0.2610.317−0.1810.424
Gender−0.2510.091−0.2440.111−0.4100.147−0.1800.443
Methotrexate−0.2350.110N/AN/A0.0280.919−0.0720.743
Cyclophosphamide−0.0460.7520.0300.8440.2210.4820.1410.536
β: β-coefficient ; p: p-value; N/A: not applicable.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Sung, W.-Y.; Lin, Y.-Z.; Hwang, D.-Y.; Lin, C.-H.; Li, R.-N.; Tseng, C.-C.; Wu, C.-C.; Ou, T.-T.; Yen, J.-H. Methylation of TET2 Promoter Is Associated with Global Hypomethylation and Hypohydroxymethylation in Peripheral Blood Mononuclear Cells of Systemic Lupus Erythematosus Patients. Diagnostics 2022, 12, 3006. https://doi.org/10.3390/diagnostics12123006

AMA Style

Sung W-Y, Lin Y-Z, Hwang D-Y, Lin C-H, Li R-N, Tseng C-C, Wu C-C, Ou T-T, Yen J-H. Methylation of TET2 Promoter Is Associated with Global Hypomethylation and Hypohydroxymethylation in Peripheral Blood Mononuclear Cells of Systemic Lupus Erythematosus Patients. Diagnostics. 2022; 12(12):3006. https://doi.org/10.3390/diagnostics12123006

Chicago/Turabian Style

Sung, Wan-Yu, Yuan-Zhao Lin, Daw-Yang Hwang, Chia-Hui Lin, Ruei-Nian Li, Chia-Chun Tseng, Cheng-Chin Wu, Tsan-Teng Ou, and Jeng-Hsien Yen. 2022. "Methylation of TET2 Promoter Is Associated with Global Hypomethylation and Hypohydroxymethylation in Peripheral Blood Mononuclear Cells of Systemic Lupus Erythematosus Patients" Diagnostics 12, no. 12: 3006. https://doi.org/10.3390/diagnostics12123006

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop